Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
 Shares Announced by Shareholders Foundation - EconoTimes)
SAN DIEGO, Jan. 27, 2016 -- The Shareholders Foundation, Inc. announces that a lawsuit was filed on behalf of certain purchasers of shares of HeartWare International Inc (NASDAQ:HTWR) over alleged Securities Laws Violations by HeartWare Intl.
Investors who purchased shares of HeartWare International Inc (NASDAQ:HTWR) have certain options and for certain investors are short and strict deadlines running. Deadline: March 22, 2016. NASDAQ:HTWR investors should contact the Shareholders Foundation at [email protected] or call +1(858) 779 - 1554.
The plaintiff claims that after the U.S. Food and Drug Administration ("FDA") issued a Warning Letter identifying numerous manufacturing and other regulatory failures at the Company's sole manufacturing facility, Defendants falsely assured investors that the Company had addressed those problems, and that they therefore posed no risk to the clinical trials or timely approval of MVAD, a pump that HeartWare International Inc is presently developing. The plaintiff says that the truth concerning the Company's failure to remediate the regulatory failures identified by the FDA and its impact on the viability of MVAD was revealed through a series of disclosures.
On September 1, 2015, HeartWare International Inc announced the acquisition of Valtech Cardio, Ltd., a manufacturer of medical devices used to treat heart disease. The Complaint alleges that this disclosure revealed significant obstacles to the timely approval of MVAD.
On September 9, 2015, HeartWare International Inc disclosed that it had paused its MVAD clinical trial to address an MVAD controller manufacturing process issue.
On October 13, 2015, HeartWare International Inc announced that following the company's investigation of causes of reported adverse effects in certain clinical trial patients, HeartWare might not re-initiate enrollment in the MVAD clinical trial in November as it had previously planned.
On January 11, 2016, HeartWare International Inc provided corporate updates and announced preliminary revenue expectations for the fourth quarter of 2015.
The plaintiff says that the announcement revealed that problems with MVAD had resulted in serious adverse events in nearly half of the patients so far implanted with the device, and that the trial would be delayed indefinitely.
Shares of HeartWare International Inc (NASDAQ:HTWR) declined from $90.71 per share in July 2015 to as low as $25.02 per share on January 12, 2016.
Those who purchased HeartWare International Inc (NASDAQ:HTWR) shares have certain options and should contact the Shareholders Foundation, Inc. by e-mail at [email protected] or call +1 (858) 779-1554.
The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
CONTACT: Shareholders Foundation, Inc.
Michael Daniels
+1 (858) 779-1554
[email protected]
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
